MARKET

CNCR

CNCR

Loncar Cancer Immunotherapy ETF
NASDAQ

Real-time Quotes | Provided by Morningstar

19.19
-0.16
-0.85%
Closed 16:00 10/23 EDT
OPEN
19.38
PREV CLOSE
19.35
HIGH
19.38
LOW
19.17
VOLUME
4.54K
TURNOVER
--
52 WEEK HIGH
22.53
52 WEEK LOW
16.87
TOTAL ASSET
32.58M
YTD YIELD
1.96%
1D
5D
1M
3M
1Y
5Y

Tools for In-Depth Analysis of CNCR, Buy or Sell Stocks and ETFs Commission-Free!

Open a Webull account and fund it to get a free stock

CNCR News

  • Aprea Therapeutics upsizes IPO amid turbulent biotech market
  • Seeking Alpha - Article.10/03 14:09
  • Health Care Sector Innovation And Insight
  • Seeking Alpha - Article.08/14 10:23
  • Biotech outperforms on M&A animal spirits
  • Seeking Alpha - Article.06/17 17:21
  • Assessing The Healthcare Selloff
  • Seeking Alpha - Article.05/04 09:47

More

Profile

Fund Name
Loncar Cancer Immunotherapy ETF
Risk
High Risk
Inception Date
2015-10-13
Benchmark
Loncar Cancer Immunotherapy TR USD*100.0%
Advisor Company
Loncar Investments
Custodian
U.S. Bank N.A
Manager
Denise Krisko, Austin Wen

Asset Allocation

38.09M
  • 99.9175%
  • 0.00%
  • 0.0825%
  • 0.00%

2019 Q2

38.09M

2019 Q1

38.87M

2018 Q4

38.54M

2018 Q3

55.70M

2018 Q2

57.66M

Dividend History

Ex-Div Date
Dividend Per Share
12/28/2018
0.0000
12/28/2017
0.3502
12/29/2015
0.1055